Kelsey Goodwin
Stock Analyst at Guggenheim
(n/a)
# 3,974
Out of 4,829 analysts
18
Total ratings
n/a
Success rate
-32.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Reiterates: Buy | n/a | $11.14 | - | 2 | Apr 29, 2025 | |
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.52 | - | 3 | Mar 28, 2025 | |
| GNLX Genelux | Initiates: Buy | $8 | $2.82 | +183.69% | 1 | Oct 29, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $99 → $105 | $73.59 | +42.68% | 2 | Sep 16, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.59 | - | 1 | Jul 31, 2024 | |
| TSVT 2seventy bio | Downgrades: Neutral | n/a | $4.99 | - | 4 | Sep 13, 2023 | |
| ACLX Arcellx | Maintains: Buy | n/a | $59.46 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $32.38 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $1.93 | - | 1 | Oct 31, 2022 |
UroGen Pharma
Apr 29, 2025
Reiterates: Buy
Price Target: n/a
Current: $11.14
Upside: -
Century Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.52
Upside: -
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.82
Upside: +183.69%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $99 → $105
Current: $73.59
Upside: +42.68%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.99
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $59.46
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $32.38
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.93
Upside: -